Cargando…
Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival
Whole-brain radiotherapy (WBRT) as a treatment for brain metastases has been questioned over the last years. This study aimed to evaluate health care levels and survival after WBRT in a cohort of lung cancer patients with brain metastases receiving WBRT in Stockholm, Sweden, from 2008 to 2019 (n = 3...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031780/ https://www.ncbi.nlm.nih.gov/pubmed/35455016 http://dx.doi.org/10.3390/life12040525 |
_version_ | 1784692476440739840 |
---|---|
author | Frisk, Gabriella Helde Frankling, Maria Warnqvist, Anna Björkhem-Bergman, Linda Hedman, Mattias |
author_facet | Frisk, Gabriella Helde Frankling, Maria Warnqvist, Anna Björkhem-Bergman, Linda Hedman, Mattias |
author_sort | Frisk, Gabriella |
collection | PubMed |
description | Whole-brain radiotherapy (WBRT) as a treatment for brain metastases has been questioned over the last years. This study aimed to evaluate health care levels and survival after WBRT in a cohort of lung cancer patients with brain metastases receiving WBRT in Stockholm, Sweden, from 2008 to 2019 (n = 384). If the patients were able to come home again was estimated using logistic regression and odds ratios (OR) and survival by using Cox regression. The median age in the cohort was 65.6 years, the median survival following WBRT was 2.4 months (interquartile range (IQR) 1.2–6.2 months), and 84 (22%) patients were not able to come home after treatment. Significantly more males could come home again after WBRT compared to women (OR = 0.37, 95%CI 0.20–0.68). Patients with performance status scores WHO 3–4 had a median survival of 1.0 months, hazard ratio (HR) = 4.69 (95%CI 3.31–6.64) versus WHO score 0–1. Patients admitted to a palliative ward before WBRT had a median survival of 0.85 months, HR = 2.26 (95%CI 1.53–3.34) versus being at home. In conclusion, patients treated with WBRT had a short median survival and 20% could not be discharged from the hospital following treatment. Significantly more women did not come home again. |
format | Online Article Text |
id | pubmed-9031780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90317802022-04-23 Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival Frisk, Gabriella Helde Frankling, Maria Warnqvist, Anna Björkhem-Bergman, Linda Hedman, Mattias Life (Basel) Article Whole-brain radiotherapy (WBRT) as a treatment for brain metastases has been questioned over the last years. This study aimed to evaluate health care levels and survival after WBRT in a cohort of lung cancer patients with brain metastases receiving WBRT in Stockholm, Sweden, from 2008 to 2019 (n = 384). If the patients were able to come home again was estimated using logistic regression and odds ratios (OR) and survival by using Cox regression. The median age in the cohort was 65.6 years, the median survival following WBRT was 2.4 months (interquartile range (IQR) 1.2–6.2 months), and 84 (22%) patients were not able to come home after treatment. Significantly more males could come home again after WBRT compared to women (OR = 0.37, 95%CI 0.20–0.68). Patients with performance status scores WHO 3–4 had a median survival of 1.0 months, hazard ratio (HR) = 4.69 (95%CI 3.31–6.64) versus WHO score 0–1. Patients admitted to a palliative ward before WBRT had a median survival of 0.85 months, HR = 2.26 (95%CI 1.53–3.34) versus being at home. In conclusion, patients treated with WBRT had a short median survival and 20% could not be discharged from the hospital following treatment. Significantly more women did not come home again. MDPI 2022-04-01 /pmc/articles/PMC9031780/ /pubmed/35455016 http://dx.doi.org/10.3390/life12040525 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Frisk, Gabriella Helde Frankling, Maria Warnqvist, Anna Björkhem-Bergman, Linda Hedman, Mattias Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival |
title | Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival |
title_full | Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival |
title_fullStr | Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival |
title_full_unstemmed | Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival |
title_short | Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival |
title_sort | evaluation of whole brain radiotherapy among lung cancer patients with brain metastases in relation to health care level and survival |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031780/ https://www.ncbi.nlm.nih.gov/pubmed/35455016 http://dx.doi.org/10.3390/life12040525 |
work_keys_str_mv | AT friskgabriella evaluationofwholebrainradiotherapyamonglungcancerpatientswithbrainmetastasesinrelationtohealthcarelevelandsurvival AT heldefranklingmaria evaluationofwholebrainradiotherapyamonglungcancerpatientswithbrainmetastasesinrelationtohealthcarelevelandsurvival AT warnqvistanna evaluationofwholebrainradiotherapyamonglungcancerpatientswithbrainmetastasesinrelationtohealthcarelevelandsurvival AT bjorkhembergmanlinda evaluationofwholebrainradiotherapyamonglungcancerpatientswithbrainmetastasesinrelationtohealthcarelevelandsurvival AT hedmanmattias evaluationofwholebrainradiotherapyamonglungcancerpatientswithbrainmetastasesinrelationtohealthcarelevelandsurvival |